

Nobuharu Tamaki

List of Publications by Citations

Source: <https://exaly.com/author-pdf/9400119/nobuharu-tamaki-publications-by-citations.pdf>

Version: 2024-04-26

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

101
papers

1,748
citations

22
h-index

38
g-index

115
ext. papers

2,424
ext. citations

5.2
avg, IF

4.17
L-index

#	Paper	IF	Citations
101	Effect of aging on risk for hepatocellular carcinoma in chronic hepatitis C virus infection. <i>Hepatology</i> , 2010 , 52, 518-27	11.2	214
100	Fetoprotein levels after interferon therapy and risk of hepatocarcinogenesis in chronic hepatitis C. <i>Hepatology</i> , 2013 , 58, 1253-62	11.2	184
99	Hepatic steatosis in chronic hepatitis C is a significant risk factor for developing hepatocellular carcinoma independent of age, sex, obesity, fibrosis stage and response to interferon therapy. <i>Hepatology Research</i> , 2010 , 40, 870-7	5.1	56
98	Expression of keratin 19 is related to high recurrence of hepatocellular carcinoma after radiofrequency ablation. <i>Oncology</i> , 2011 , 80, 278-88	3.6	55
97	A predictive model of response to peginterferon ribavirin in chronic hepatitis C using classification and regression tree analysis. <i>Hepatology Research</i> , 2010 , 40, 251-60	5.1	53
96	Association of gene expression involving innate immunity and genetic variation in interleukin 28B with antiviral response. <i>Hepatology</i> , 2012 , 55, 20-9	11.2	52
95	Changes in plasma vascular endothelial growth factor at 8 weeks after sorafenib administration as predictors of survival for advanced hepatocellular carcinoma. <i>Cancer</i> , 2014 , 120, 229-37	6.4	51
94	Wisteria floribunda agglutinin positive human Mac-2-binding protein as a predictor of hepatocellular carcinoma development in chronic hepatitis C patients. <i>Hepatology Research</i> , 2015 , 45, E82-8	5.1	48
93	L-carnitine Reduces Muscle Cramps in Patients With Cirrhosis. <i>Clinical Gastroenterology and Hepatology</i> , 2015 , 13, 1540-3	6.9	40
92	Non-invasive prediction of hepatocellular carcinoma development using serum fibrosis marker in chronic hepatitis C patients. <i>Journal of Gastroenterology</i> , 2014 , 49, 1495-503	6.9	38
91	Novel quantitative assessment system of liver steatosis using a newly developed attenuation measurement method. <i>Hepatology Research</i> , 2018 , 48, 821-828	5.1	37
90	Naturally occurring, resistance-associated hepatitis C virus NS5A variants are linked to interleukin-28B genotype and are sensitive to interferon-based therapy. <i>Hepatology Research</i> , 2015 , 45, E115-21	5.1	35
89	Noninvasive estimation of fibrosis progression overtime using the FIB-4 index in chronic hepatitis C. <i>Journal of Viral Hepatitis</i> , 2013 , 20, 72-6	3.4	34
88	Relationship between polymorphisms of the inosine triphosphatase gene and anaemia or outcome after treatment with pegylated interferon and ribavirin. <i>Antiviral Therapy</i> , 2011 , 16, 685-94	1.6	34
87	Urinary excretion of the water channel aquaporin \u00bd correlated with the pharmacological effect of tolvaptan in cirrhotic patients with ascites. <i>Journal of Gastroenterology</i> , 2016 , 51, 620-7	6.9	31
86	Wisteria floribunda agglutinin-positive Mac-2 binding protein predicts early occurrence of hepatocellular carcinoma after sustained virologic response by direct-acting antivirals for hepatitis C virus. <i>Hepatology Research</i> , 2018 , 48, 1131-1139	5.1	31
85	Hyperglycemia is a significant prognostic factor of hepatocellular carcinoma after curative therapy. <i>World Journal of Gastroenterology</i> , 2013 , 19, 249-57	5.6	31

84	Tenofovir alafenamide for hepatitis B virus infection including switching therapy from tenofovir disoproxil fumarate. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2019 , 34, 2004-2010	4	29
83	Impact of pre-sarcopenia in sorafenib treatment for advanced hepatocellular carcinoma. <i>PLoS ONE</i> , 2018 , 13, e0198812	3.7	26
82	Genetic variation near interleukin 28B and the risk of hepatocellular carcinoma in patients with chronic hepatitis C. <i>Journal of Gastroenterology</i> , 2014 , 49, 1152-62	6.9	26
81	Risk factors for exceeding the Milan criteria after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Liver Transplantation</i> , 2014 , 20, 291-7	4.5	24
80	Elastin Fiber Accumulation in Liver Correlates with the Development of Hepatocellular Carcinoma. <i>PLoS ONE</i> , 2016 , 11, e0154558	3.7	23
79	Up-to-seven criteria as a useful predictor for tumor downstaging to within Milan criteria and Child-Pugh grade deterioration after initial conventional transarterial chemoembolization. <i>Hepatology Research</i> , 2018 , 48, 442-450	5.1	22
78	Prediction of diuretic response to tolvaptan by a simple, readily available spot urine Na/K ratio. <i>PLoS ONE</i> , 2017 , 12, e0174649	3.7	21
77	Sorafenib-Regorafenib Sequential Therapy in Japanese Patients with Unresectable Hepatocellular Carcinoma-Relative Dose Intensity and Post-Regorafenib Therapies in Real World Practice. <i>Cancers</i> , 2019 , 11,	6.6	20
76	Relative dose intensity over the first four weeks of lenvatinib therapy is a factor of favorable response and overall survival in patients with unresectable hepatocellular carcinoma. <i>PLoS ONE</i> , 2020 , 15, e0231828	3.7	20
75	Non-alcoholic fatty liver disease fibrosis score and FIB-4 scoring system could identify patients at risk of systemic complications. <i>Hepatology Research</i> , 2015 , 45, 667-75	5.1	19
74	Genetic Polymorphisms of IL28B and PNPLA3 Are Predictive for HCV Related Rapid Fibrosis Progression and Identify Patients Who Require Urgent Antiviral Treatment with New Regimens. <i>PLoS ONE</i> , 2015 , 10, e0137351	3.7	19
73	Hepatitis B surface antigen reduction by switching from long-term nucleoside/nucleotide analogue administration to pegylated interferon. <i>Journal of Viral Hepatitis</i> , 2017 , 24, 672-678	3.4	18
72	Prospective comparison of real-time tissue elastography and serum fibrosis markers for the estimation of liver fibrosis in chronic hepatitis C patients. <i>Hepatology Research</i> , 2014 , 44, 720-7	5.1	18
71	Resistance-Associated NS5A Variants of Hepatitis C Virus Are Susceptible to Interferon-Based Therapy. <i>PLoS ONE</i> , 2015 , 10, e0138060	3.7	18
70	Changes in the components and content of biological water in the brain of experimental hydrocephalic rabbits. <i>Journal of Neurosurgery</i> , 1990 , 73, 274-8	3.2	18
69	Wisteria floribunda agglutinin-positive mac-2 binding protein as an age-independent fibrosis marker in nonalcoholic fatty liver disease. <i>Scientific Reports</i> , 2019 , 9, 10109	4.9	17
68	Non-invasive liver fibrosis assessment correlates with collagen and elastic fiber quantity in patients with hepatitis C virus infection. <i>Hepatology Research</i> , 2019 , 49, 33-41	5.1	17
67	New diagnostic technique to evaluate hepatic steatosis using the attenuation coefficient on ultrasound B mode. <i>PLoS ONE</i> , 2019 , 14, e0221548	3.7	14

66	Risk assessment of hepatocellular carcinoma development by magnetic resonance elastography in chronic hepatitis C patients who achieved sustained virological responses by direct-acting antivirals. <i>Journal of Viral Hepatitis</i> , 2019 , 26, 893-899	3.4	14
65	Real-life experience of lusutrombopag for cirrhotic patients with low platelet counts being prepared for invasive procedures. <i>PLoS ONE</i> , 2019 , 14, e0211122	3.7	14
64	Clinical Utility of Mac-2 Binding Protein Glycosylation Isomer in Chronic Liver Diseases. <i>Annals of Laboratory Medicine</i> , 2021 , 41, 16-24	3.1	14
63	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Journal of Gastroenterology</i> , 2021 , 56, 951-963	6.9	14
62	Randomised clinical trial: Pemafibrate, a novel selective peroxisome proliferator-activated receptor α modulator (SPPARM α) versus placebo in patients with non-alcoholic fatty liver disease. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 , 54, 1263-1277	6.1	14
61	Irregular vascular pattern by contrast-enhanced ultrasonography and high serum Lens culinaris agglutinin-reactive fraction of alpha-fetoprotein level predict poor outcome after successful radiofrequency ablation in patients with early-stage hepatocellular carcinoma. <i>Cancer Medicine</i> , 2021 , 5, 3111-3120	4.8	13
60	Reduced organic anion transporter expression is a risk factor for hepatocellular carcinoma in chronic hepatitis C patients: a propensity score matching study. <i>Oncology</i> , 2014 , 86, 53-62	3.6	13
59	Prediction of reversible ischemia after coronary artery bypass grafting by positron emission tomography. <i>Journal of Cardiology</i> , 1991 , 21, 193-201	3	13
58	Strategy for advanced hepatocellular carcinoma based on liver function and portal vein tumor thrombosis. <i>Hepatology Research</i> , 2020 , 50, 1375-1385	5.1	13
57	Three criteria for radiological response on survival in patients with hepatocellular carcinoma treated with lenvatinib. <i>Hepatology Research</i> , 2020 , 50, 137-143	5.1	13
56	Serum Wisteria Floribunda Agglutinin-Positive Sialylated Mucin 1 as a Marker of Progenitor/Biliary Features in Hepatocellular Carcinoma. <i>Scientific Reports</i> , 2017 , 7, 244	4.9	12
55	Novel Pretreatment Scoring Incorporating C-reactive Protein to Predict Overall Survival in Advanced Hepatocellular Carcinoma with Sorafenib Treatment. <i>Liver Cancer</i> , 2016 , 5, 257-268	9.1	12
54	Baseline and Early Predictors of Good Patient Candidates for Second-Line after Sorafenib Treatment in Unresectable Hepatocellular Carcinoma. <i>Cancers</i> , 2019 , 11,	6.6	11
53	Prediction of Hepatocellular Carcinoma After Sustained Virological Responses Using Magnetic Resonance Elastography. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 2616-2618	6.9	11
52	Comparison of medication adherence and satisfaction between entecavir and tenofovir alafenamide therapy in chronic hepatitis B. <i>Journal of Medical Virology</i> , 2020 , 92, 1355-1358	19.7	11
51	Validation of hepatocellular carcinoma risk scores in Japanese chronic hepatitis B cohort receiving nucleot(s)ide analog. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2020 , 35, 1595-1601	4	10
50	Non-invasive methods for imaging hepatic steatosis and their clinical importance in NAFLD. <i>Nature Reviews Endocrinology</i> , 2022 , 18, 55-66	15.2	10
49	Clinical utility of 30% relative decline in MRI-PDFF in predicting fibrosis regression in non-alcoholic fatty liver disease. <i>Gut</i> , 2021 ,	19.2	10

48	Hepatitis B surface antigen reduction as a result of switching from long-term entecavir administration to tenofovir. <i>JGH Open</i> , 2020 , 4, 429-432	1.8	9
47	Impaired brain activity in cirrhotic patients with minimal hepatic encephalopathy: Evaluation by near-infrared spectroscopy. <i>Hepatology Research</i> , 2014 , 44, 319-26	5.1	8
46	Longitudinal association of magnetic resonance elastography-associated liver stiffness with complications and mortality.. <i>Alimentary Pharmacology and Therapeutics</i> , 2021 ,	6.1	8
45	Evidence-based clinical practice guidelines for nonalcoholic fatty liver disease/nonalcoholic steatohepatitis 2020. <i>Hepatology Research</i> , 2021 , 51, 1013-1025	5.1	7
44	Use of the Serum Agglutinin-Positive Mac2 Binding Protein as a Marker of Gastroesophageal Varices and Liver-Related Events in Chronic Hepatitis C Patients. <i>Diagnostics</i> , 2020 , 10,	3.8	6
43	Angled rigid neuroendoscope for continuous intraoperative visual monitoring: technical note. <i>Journal of Clinical Neuroscience</i> , 2001 , 8, 148-50	2.2	6
42	Risk Difference of Liver-Related and Cardiovascular Events by Liver Fibrosis Status in Nonalcoholic Fatty Liver Disease. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	6
41	MRE plus FIB-4 (MEFIB) versus FAST in detection of candidates for pharmacological treatment of NASH-related fibrosis. <i>Hepatology</i> , 2021 ,	11.2	6
40	Expert Panel Review to Compare FDA and EMA Guidance on Drug Development and Endpoints in Nonalcoholic Steatohepatitis. <i>Gastroenterology</i> , 2021 ,	13.3	5
39	Detectable HBV DNA during nucleos(t)ide analogues stratifies predictive hepatocellular carcinoma risk score. <i>Scientific Reports</i> , 2020 , 10, 13021	4.9	5
38	Wisteria floribunda Agglutinin-Positive Mac-2 Binding Protein but not Fetoprotein as a Long-Term Hepatocellular Carcinoma Predictor. <i>International Journal of Molecular Sciences</i> , 2020 , 21,	6.3	4
37	Changes in hepatitis C viral load during first 14 days can predict the undetectable time point of serum viral load by pegylated interferon and ribavirin therapy. <i>Hepatology Research</i> , 2011 , 41, 217-24	5.1	4
36	Placebo Effect on Progression and Regression in Non-Alcoholic Steatohepatitis. Evidence from a Meta-Analysis.. <i>Hepatology</i> , 2022 ,	11.2	4
35	Agglutinin-Positive Mac-2 Binding Protein as a Screening Tool for Significant Liver Fibrosis in Health Checkup. <i>International Journal of Molecular Sciences</i> , 2020 , 22,	6.3	4
34	Diagnostic accuracy of two-dimensional shear wave elastography and transient elastography in nonalcoholic fatty liver disease. <i>Therapeutic Advances in Gastroenterology</i> , 2021 , 14, 17562848211050436	4.7	4
33	Liver fibrosis and fatty liver as independent risk factors for cardiovascular disease. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2960-2966	4	4
32	Pretreatment Gastric Lavage Reduces Postoperative Bleeding after Endoscopic Submucosal Dissection for Gastric Neoplasms. <i>PLoS ONE</i> , 2016 , 11, e0149235	3.7	4
31	Dynamic evaluation of hepatocellular carcinoma prediction models in patients with chronic hepatitis B receiving nucleotide/nucleoside analogue treatment. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 787-794	3.4	3

30	Change in Fibrosis 4 Index as Predictor of High Risk of Incident Hepatocellular Carcinoma After Eradication of Hepatitis C Virus. <i>Clinical Infectious Diseases</i> , 2021 , 73, e3349-e3354	11.6	3
29	Early experience of atezolizumab plus bevacizumab therapy in Japanese patients with unresectable hepatocellular carcinoma in real-world practice. <i>Investigational New Drugs</i> , 2021 , 1	4.3	3
28	Early radiological response evaluation with response evaluation criteria in solid tumors 1.1 stratifies survival in hepatocellular carcinoma patients treated with lenvatinib. <i>JGH Open</i> , 2020 , 4, 1183-1190	1.8	2
27	Clinical Utility of Change in Nonalcoholic Fatty Liver Disease Activity Score and Change in Fibrosis in NAFLD. <i>Clinical Gastroenterology and Hepatology</i> , 2021 , 19, 2673-2674.e3	6.9	2
26	Validation of albumin, bilirubin, and platelet criteria for avoiding screening endoscopy in patients with advanced fibrosis. <i>Hepatology Research</i> , 2020 , 50, 996-999	5.1	2
25	Viable myocardium identified by reinjection thallium-201 imaging: comparison with regional wall motion and metabolic activity on FDG-PET. <i>Journal of Cardiology</i> , 1992 , 22, 283-93	3	2
24	Utility of Ultrasound-Guided Attenuation Parameter for Grading Steatosis With Reference to MRI-PDFF in a Large Cohort. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
23	Atherosclerotic cardiovascular disease risk difference in metabolic dysfunction-associated fatty liver disease and nonalcoholic fatty liver disease. <i>Hepatology Research</i> , 2021 , 51, 1172-1173	5.1	2
22	Impaired brain function improved by L-carnitine in patients with cirrhosis: evaluation using near-infrared spectroscopy. <i>Scientific Reports</i> , 2020 , 10, 13566	4.9	2
21	Changes of liver stiffness measured by magnetic resonance elastography during direct-acting antivirals treatment in patients with chronic hepatitis C. <i>Journal of Medical Virology</i> , 2021 , 93, 3744-3751	19.7	2
20	Diagnostic Accuracy of Two-Dimensional Shear Wave Elastography for Liver Fibrosis: A Multicenter Prospective Study. <i>Clinical Gastroenterology and Hepatology</i> , 2021 ,	6.9	2
19	Tenofovir alafenamide for prevention and treatment of hepatitis B virus reactivation and de novo hepatitis. <i>JGH Open</i> , 2021 , 5, 1085-1091	1.8	2
18	Four cases with advanced hepatocellular carcinoma who achieved long survival, after surgical resection following to down-staging therapies. <i>Acta Hepatologica Japonica</i> , 2016 , 57, 649-655	0.3	1
17	Two-step strategy, FIB-4 followed by magnetic resonance elastography, for detecting advanced fibrosis in NAFLD.. <i>Clinical Gastroenterology and Hepatology</i> , 2022 ,	6.9	1
16	Letter: predictive role of magnetic resonance elastography in chronic liver disease-still a long way to go. AuthorsTreply.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 622-623	6.1	1
15	A case of unresectable hepatocellular carcinoma maintaining stable disease by using anti-vascular endothelial growth factor receptor antibody after the exacerbation of psoriasis due to small-molecule kinase inhibition. <i>Acta Hepatologica Japonica</i> , 2020 , 61, 513-519	0.3	1
14	Hepatitis B core-related antigen predicts disease progression and hepatocellular carcinoma in hepatitis B e antigen-negative chronic hepatitis B patients. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2021 , 36, 2943-2951	4	1
13	Prognosis of intrahepatic cholangiocarcinoma stratified by albumin-bilirubin grade. <i>Hepatology Research</i> , 2021 , 51, 902-908	5.1	1

12	Attenuation coefficient (ATT) measurement for liver fat quantification in chronic liver disease. <i>Journal of Medical Ultrasonics (2001)</i> , 2021 , 48, 481-487	1.4	○
11	Clinical evaluation of Elecsys PIVKA-II for patients with advanced hepatocellular carcinoma.. <i>PLoS ONE</i> , 2022 , 17, e0265235	3.7	○
10	A validation study of after direct-acting antivirals recommendation for surveillance score for the development of hepatocellular carcinoma in patients with hepatitis C virus infection who had received direct-acting antiviral therapy and achieved sustained virological response.. <i>JGH Open</i> , 2022 , 6, 20-28	1.8	○
9	Prognostic utility of magnetic resonance elastography and MEFIB index in predicting liver-related outcomes and mortality in individuals at risk of and with nonalcoholic fatty liver disease.. <i>Therapeutic Advances in Gastroenterology</i> , 2022 , 15, 17562848221093869	4.7	○
8	Reply. <i>Clinical Gastroenterology and Hepatology</i> , 2019 , 17, 1419-1420	6.9	
7	Imaging Findings of Hepatocellular Carcinoma that Developed after HCV Eradication with Direct-Acting Antivirals. <i>Acta Hepatologica Japonica</i> , 2019 , 60, 46-48	0.3	
6	Fibrosis and fibrogenesis 2015 , 46-52		
5	Two cases of acute liver failure caused by hepatitis A which were negative for serum IgM-HA antibody at the early stage of the onset. <i>Acta Hepatologica Japonica</i> , 2013 , 54, 553-558	0.3	
4	Letter: association of laboratory indexes and magnetic resonance elastography-associated liver stiffness with complications and mortality-authorsTreply.. <i>Alimentary Pharmacology and Therapeutics</i> , 2022 , 55, 626-627	6.1	
3	IV. Evaluation of Liver Fibrosis and Steatosis in Non-alcoholic Fatty Liver Disease. <i>The Journal of the Japanese Society of Internal Medicine</i> , 2020 , 109, 34-41	0	
2	Diagnostic accuracy of hepatocellular carcinoma risk prediction models during antiviral therapy in chronic hepatitis B patients. <i>Hepatology Research</i> , 2021 , 51, 1170-1171	5.1	
1	Reply to Wang et al. <i>Journal of Viral Hepatitis</i> , 2021 , 28, 1335-1336	3.4	